Recently, the FDA announced the approval of a new drug, vamorolone, as a treatment for Duchenne muscular dystrophy (DMD), a genetic muscle disease that usually affects young boys. Understandably, this…
Continue Reading
IBM patients battle for veterans benefits
Recently, two members of TMA’s Military Veterans with Myositis Affinity Group were successful in acquiring disability benefits from the Veterans Administration. These benefits are significant. Not only are these former…
Continue Reading
Paula Eichenbrenner joins TMA
Starting November 29, 2023, TMA will have a new executive director. After a months-long national search, TMA’s Board of Directors has found the perfect candidate to serve as TMA’s executive…
Continue Reading
Copay accumulator programs struck down
In a victory for patients, a federal judge recently struck down a policy that allowed health insurance plans to use copay accumulator and maximizer programs, thereby charging patients more for…
Continue Reading
Peter Frampton leads the fight against myositis from front stage
When an individual goes above and beyond, representing, raising awareness, and contributing financially to the work of The Myositis Association (TMA), it is more than fitting to present them with…
Continue Reading